Abeona Therapeutics Inc. (ABEO)
$
6.24
+0.08 (1.28%)
Key metrics
Financial statements
Free cash flow per share
-1.2656
Market cap
328.4 Million
Price to sales ratio
0
Debt to equity
0.5792
Current ratio
4.9002
Income quality
1.3552
Average inventory
0
ROE
-0.8645
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases, reported depreciation and amortization expenses of $2,907,000.00 reflecting the wear and tear of its assets. The company demonstrated its financial health with an income before tax of -$63,734,000.00 showcasing its pre-tax profitability. With a weighted average number of diluted shares outstanding of $41,048,206.00 the company highlights potential dilution effects that could arise. Operating expenses were also noted, as the company reported selling, general, and administrative expenses of $26,944,000.00 indicating its operational overhead costs. Furthermore, the weighted average number of shares outstanding is $41,048,206.00 which underscores the company’s shareholder base and their potential influence on its market strategies. Abeona's lead program, EB-101, is an autologous, gene-corrected cell therapy currently in Phase III clinical trials for recessive dystrophic epidermolysis bullosa, while the company is also advancing other therapeutic candidates targeting conditions such as Sanfilippo syndrome type A and cystic fibrosis. Within the financial landscape, the stock is affordable at $6.16 suitable for budget-conscious investors. However, it is noteworthy that the stock has a low average trading volume of $1,609,714.00 indicating lower market activity which may affect liquidity. With a market capitalization of $319,217,808.00 the company is classified as a small-cap player in the biopharmaceutical field. As a key player in the Biotechnology industry, Abeona contributes significantly to the overall market landscape, particularly through its innovative approaches to treating rare genetic disorders. Additionally, it belongs to the Healthcare sector, continuously driving innovation and growth within this vital area of healthcare. The ongoing development of its AAV-based gene therapy programs through the AIM vector platform exemplifies Abeona’s commitment to pioneering treatments, further enhancing its role in the evolving biopharmaceutical industry.
Is Abeona Therapeutics Inc. (ABEO) a good investment?
Investing in Abeona Therapeutics Inc. (ABEO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Abeona Therapeutics Inc. (ABEO)'s stock forecast?
Analysts predict Abeona Therapeutics Inc. stock to fluctuate between $3.93 (low) and $7.32 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abeona Therapeutics Inc.'s market capitalization?
As of 2025-05-30, Abeona Therapeutics Inc.'s market cap is $319,217,808, based on 51,156,700 outstanding shares.
How does Abeona Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abeona Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Abeona Therapeutics Inc. pay dividends?
Abeona Therapeutics Inc. pays dividends. The current dividend yield is 8.55%, with a payout of $0.59 per share.
How can I buy Abeona Therapeutics Inc. (ABEO) stock?
To buy Abeona Therapeutics Inc. (ABEO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABEO. Place an order (Market, Limit, etc.).
What is the best time to invest in Abeona Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Abeona Therapeutics Inc. stock ever split?
Abeona Therapeutics Inc.'s last stock split was 1:25 on 2022-07-05.
How did Abeona Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.55 | Growth: -38.74%.
Where can I find Abeona Therapeutics Inc.'s investor relations reports?
Visit https://www.abeonatherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abeona Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Abeona Therapeutics Inc. stock?
All-time high: $94.75 (2021-02-09) | All-time low: $2.19 (2023-02-24).
What are the key trends affecting Abeona Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Greg Gin - Vice President-Investor Relations and Communications Vish Seshadri - Chief Executive Officer Madhav Vasanthavada - Chief Commercial Officer and Head-Business Development Brian Kevany - Chief Technical Officer Joe Vazzano - Chief Financial Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Steven Willey - Stifel Ram Selvaraju - H.C. Wainwright James Molloy - Alliance Global Partners David Bautz - Zacks Small Cap Research Operator Good day and welcome to the Abeona Therapeutics First Quarter 2025 Conference Call.
globenewswire.com
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment - - Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey - CLEVELAND and CHICAGO, May 14, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Ann & Robert H.
globenewswire.com
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration (FDA) approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025.
reuters.com
The U.S. Food and Drug Administration on Tuesday approved Abeona Therapeutics' gene therapy for a rare skin disorder.
globenewswire.com
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile - - ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 - - Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN - - Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA - - Abeona Therapeutics ® to host conference call today, Tuesday, April 29, 2025, at 8:00 a.m. ET - CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin') (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease.
seekingalpha.com
Abeona Therapeutics is poised for significant growth in 2025, with potential FDA approvals for Pz-cel and UX111, driving our Buy rating. Pz-cel, targeting RDEB, shows promising clinical data and commercial prospects, with an expected FDA decision by April 29, 2025. UX111, aimed at MPS IIIA, also holds strong potential, with an FDA decision anticipated by August 18, 2025, and substantial market opportunities.
seekingalpha.com
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Greg Gin – Vice President-Investor Relations and Communications Vish Seshadri – Chief Executive Officer Madhav Vasanthavada – Chief Commercial Officer and Head-Business Development Brian Kevany – Chief Technical Officer Joe Vazzano – Chief Financial Officer Conference Call Participants Kristen Kluska – Cantor François Brisebois – Oppenheimer Ram Selvaraju – H.C. Wainwright David Bautz – Zacks Small Cap Research Operator Greetings.
globenewswire.com
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
globenewswire.com
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
Abeona Therapeutics Inc.'s lead program, pz-cel, is an autologous gene therapy for RDEB, showing significant wound healing and pain reduction in clinical trials. Despite a CRL from the FDA, Abeona resubmitted its BLA, with a new PDUFA date set for April 29, 2025. ABEO stock remains undervalued, with potential for significant gains if pz-cel is approved, supported by strong cash reserves and a valuable PRV.
See all news
